NSE · HIKAL · Pharmaceuticals
Hikal Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹16,95,20,00,000 Cr with net profit ₹-48,80,00,000 Cr — a -2.88% net margin, versus 2.81% the period before.
Shareholding
As of 2026-06-30
- Promoter68.85%
- Public22.93%
- FII0.99%
- DII7.24%
73,527 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.3× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #7 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.5 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.72 | 12.98% | 11.5% |
| Hikal Limited(this company) | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.27 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashHikal Limited is listed on the Indian markets with a market capitalization of Rs 2774 Cr. The company reported annual revenue of Rs 1864.8 Cr. The earnings per share (EPS) stands at 7.35, with a price-to-earnings (PE) ratio of 54.44. The book value is Rs 102.21, and the debt-to-equity ratio is 0.65.
Positives
- +Promoter shareholding is significant at 68.85% as of Jun 30, 2026.
- +The company has no promoter pledged shares reported.
- +The debt-to-equity ratio of 0.65 is moderate.
Negatives
- −The Return on Capital Employed (ROCE) is low at 3.56%.
- −Return on Equity (ROE) is 7.4%, which is relatively low.
- −The company recorded a negative net profit of -Rs 34.9 Cr in Sept 2025.
- −The Price-to-Earnings (PE) ratio is high at 54.44 relative to the EPS of 7.35.
Financial Performance
Hikal Limited's latest annual revenue was Rs 1864.8 Cr. Quarterly revenues have varied, with Rs 447.7 Cr in Dec 2024, Rs 552.4 Cr in Mar 2025, Rs 380.4 Cr in Jun 2025, Rs 318.5 Cr in Sept 2025, Rs 494.3 Cr in Dec 2025, and Rs 519.4 Cr in Mar 2026. Net profit on a quarterly basis ranged from a high of Rs 50.2 Cr in Mar 2025 to a low of -Rs 34.9 Cr in Sept 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 7.4% and Return on Capital Employed (ROCE) is 3.56%. The latest reported earnings per share (EPS) is 7.35. Quarterly net profits have recently varied, including -Rs 22.7 Cr in Jun 2025 and 14.6 Cr in Mar 2026 from annual data, and -Rs 34.9 Cr in Sept 2025 from quarterly data, indicating fluctuating profitability.
Balance Sheet
Hikal Limited has a debt-to-equity ratio of 0.65. The book value per share is Rs 102.21. The market capitalization stands at Rs 2774 Cr. There are no reported promoter pledges.
Ownership & Pledges
Total institutional holding is 8.22%. There are no shares pledged by the promoters.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.